Acneiform eruption / acneiform dermatitis / acneiform rash

• (2025): Aftab M+, Cureus 17(6), e86447

Acute febrile neutrophilic dermatosis (Sweet's / Sweet syndrome)

• (2021): Yang JJ+, Dermatol Ther 34(1), e14461 (14 cases) [REVIEW]

Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))

• (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 58%
• (2019): Clapes V+, Pharmaceut Med 33(1), 2123%

Cutaneous toxicity / skin toxicity

• (2015): Macdonald JB+, J Am Acad Dermatol 72(2), 203 [REVIEW]

Edema / fluid retention

• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92944%

Exanthems

• (2018): Sanmartin O, Curr Probl Dermatol 53, 93

Hand–foot syndrome (palmar–plantar erythrodysesthesia)

• (2023): Yeh CN+, Biol Trace Elem Res Mar, Online ahead of print [REVIEW]
• (2018): Sanmartin O, Curr Probl Dermatol 53, 93

Ichthyosis

• (2022): Park JS+, J Eur Acad Dermatol Venereol Sep, Online ahead of print [REVIEW] (association)

Pigmentation (Skin) (includes hyperpigmentation)

• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92919%

Pyoderma gangrenosum

• (2022): Khoshnam-Rad N+, Anticancer Drugs 33(1), e1-e8 (15 cases)

Rash

• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92914%

Nail disorder

• (2014): Prescrire Int 23(151), 180

Oral changes

• (2025): Nemeș A+, Dent J (Basel) 13(10), 439 [REVIEW] (bucco-dental toxicities)

Arrhythmias

• (2021): Cheng M+, Front Cardiovasc Med Nov (e-Collection) [REVIEW]

Hypertension

• (2020): Gadd M+, Cancer Rep (Hoboken) Aug, e1275
• (2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]

Thyroid dysfunction

• (2024): Luna NA+, J ASEAN Fed Endocr Soc 39(2), 20-2640%
• (2023): Leo S+, Ann Endocrinol (Paris) Mar, Online ahead of print [REVIEW]

Thyroiditis

• (2017): Rizzo LFL+, Medicina (B Aires) 77(5), 394

Weight gain

• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92912%

Gastrointestinal adverse reaction

• (2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]

Gastrointestinal disorder / discomfort

• (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 34%
• (2019): Clapes V+, Pharmaceut Med 33(1), 2117%
• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92932%

Hepatic (liver) disorder / hepatobiliary disorder / hepatic (liver) dysfunction

• (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 14%

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

• (2019): Carretero-Gonzalez A+, Medicine (Baltimore) 98(47), e18098 (3 cases) (previous treatment with immune checkpoint inhibitors also implicated)
• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92912%
• (2015): Karczmarek-Borowska B+, Contemp Oncol (Pozn) 19(2), 87 [REVIEW]

Cytopenia

• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 9298%

Asthenia / fatigue

• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92938%
• (2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]

Muscle spasm

• (2016): Yamada M+, Rinsho Ketsueki 57(4), 489
• (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92919%

Eyelashes – trichomegaly / eyelash hypertrichosis / eyelash megalotrichosis

• (2024): Gershon R+, PLoS One 19(12), e0313326 [REVIEW]

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury

• (2023): Collotta D+, G Ital Nefrol (Italian) 40(Suppl 81), 2023-S81 [REVIEW]

Respiratory disorder

• (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 10%
• (2019): Clapes V+, Pharmaceut Med 33(1), 2112%

Adverse effects / adverse reactions

• (2025): Budău LV+, Pharmaceuticals (Basel) 18(7), 959 [REVIEW] (drug interaction)
• (2025): Kyriacou NM+, Clin Transl Sci 18(5), e70224 [REVIEW]
• (2023): Boskabadi SJ+, J Oncol Pharm Pract May, Online ahead of print [REVIEW]

Infection

• (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 16%